Evidence map›Paper›PMID 35379503›Full record

GuidelineJournal of the American College of Cardiology2022

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Paul A Heidenreich, Biykem Bozkurt, David Aguilar, Larry A Allen, Joni J Byun, Monica M Colvin, Anita Deswal, Mark H Drazner, Shannon M Dunlay, Linda R Evers and 16 more

Erratum issued 12 registry-linked trialsAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT06142474. Cited by 1,362 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,362citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06142474 phase3recruiting

The Potential Beneficial Effects of SGLT2 Inhibitors in Patients With Acute Decompensated Heart Failure During Ventilator Weaning: a Prospective Multicenter Cohort Study.

Ran2022Enrolled450Registered outcomes7Posted comparisons0ConditionsHeart Failure Acute, Ventilator LungArmsSGLT2 inhibitor
Open the trial in the graph
NCT06706791 phase4recruitingstarted 2025, after this paper: background citation

Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II

Ran2025Enrolled156Registered outcomes2Posted comparisons0ConditionsChronic Heart FailureArmsempagliflozin 10 mg
Open the trial in the graph
NCT07482943 phase4recruitingstarted 2026, after this paper: background citation

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Ran2026Enrolled30Registered outcomes13Posted comparisons0ConditionsCardiovascular Diseases, Dapagliflozin, Fontan, Heart FailureArmsDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
Open the trial in the graph
NCT05967247 nacompletednot on this mapstarted 2023, after this paper: background citation

The Effect of App-Based Mindfulness-Based Stress on Physiological and Psychological Factors in Patients With Heart Failure: A Randomized Controlled Trial

TypeinterventionalSponsorNational Taiwan University HospitalRan2023 to 2024Enrolled68ConditionsHeart FailureArmsThe experimental group used App for MBSR intervention, the "Heart Care Life" app, APP
NCT06074887 nacompletednot on this mapstarted 2024, after this paper: background citation

The Effect of a Nurse-led, Transtheoretical Model-based Home Education and Follow-up Programme on Self-care Behaviour in Patients With Heart Failure: A Randomized Controlled Trial

TypeinterventionalSponsorCukurova UniversityRan2024 to 2024Enrolled63ConditionsHeart FailureArmstranstheoretical model-based intervention
NCT06099028 completednot on this map

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China: a Retrospective Database-based Study

TypeobservationalSponsorPeking University First HospitalRan2021 to 2023Enrolled22,500ConditionsHeart FailureArmsno intervention
NCT06161649 naunknown statusnot on this mapstarted 2023, after this paper: background citation

To Investigate Whether a Continuous Intelligent and Automated Mobile Education System Can Improve Knowledge, Self-care, Emotional Stress, Self-efficacy and Quality of Life in Patients With Heart Failure

TypeinterventionalSponsorChang Gung Memorial HospitalRan2023 to 2026Enrolled138ConditionsAcute Decompensated Heart FailureArmsaccepting the operation process of automated intelligent education software system
NCT06398977 narecruitingnot on this mapstarted 2024, after this paper: background citation

Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study

TypeinterventionalSponsorSichuan Academy of Medical SciencesRan2024 to 2026Enrolled70ConditionsPeritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 InhibitorsArmsDapagliflozin
NCT06624293 completednot on this mapstarted 2024, after this paper: background citation

Access BNP Assay Clinical Subject Sample Collection Enrollment Study Protocol

TypeobservationalSponsorBeckman Coulter, Inc.Ran2024 to 2025Enrolled1,100ConditionsHeart FailureArmsBNP
NCT06921603 narecruitingnot on this mapstarted 2025, after this paper: background citation

Point-of-Care Ultrasound-Guided Diuresis for Acute Decompensated Heart Failure to Reduce 30-Day Readmissions and Acute Kidney Injury

TypeinterventionalSponsorUniversity of PittsburghRan2025 to 2026Enrolled588ConditionsHeart Decompensation, Acute, Acute Kidney InjuriesArmsFurosemide (Standard Diuretic) Treatment, POCUS-Assessed Diuretic Management
NCT07337577 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Large Language Model-Generated Messages to Improve Guideline-Directed Medical Therapy in Heart Failure

TypeinterventionalSponsorBrigham and Women's HospitalRan2026 to 2027Enrolled500ConditionsHeart FailureArmsLLM-GDMT Clinical Decision Support Tool
NCT07464249 nacompletednot on this mapstarted 2024, after this paper: background citation

Comparison of the Effectiveness of Bolus and Infusion Diuretic Therapy in the Management of Acute Heart Failure in Emergency Departments: a Randomised, Double-blind Clinical Study

TypeinterventionalSponsorSultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyRan2024 to 2024Enrolled50ConditionsAcute Decompensated Heart Failure (ADHF)ArmsFurosemide Bolus, Furosemide Continuous İnfusion
3 · Its place in the literature

Who cites it

1,362 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. The Impact of β-Blocker Therapy on Peak VOAmerican journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Palliative care interventions for thoracic cancer: a systematic review and meta-analysis identifying the core elements.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

1,302 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Paul A Heidenreich
Biykem Bozkurt
David Aguilar
Larry A Allen
Joni J Byun
Monica M Colvin
Anita Deswal
Mark H Drazner
Shannon M Dunlay
Linda R Evers
James C Fang
Savitri E Fedson
Gregg C Fonarow
Salim S Hayek
Adrian F Hernandez
Prateeti Khazanie
Michelle M Kittleson
Christopher S Lee
Mark S Link
Carmelo A Milano
Lorraine C Nnacheta
Alexander T Sandhu
Lynne Warner Stevenson
Orly Vardeny
Amanda R Vest
Clyde W Yancy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.

methodsA comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. STRUCTURE: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.

Indexed as

CardiologyHeart FailureAmerican Heart AssociationHumansResearch ReportUnited StatesACC/AHA Clinical Practice GuidelinesACE inhibitorsacute decompensated heart failureangiotensin and neprilysin receptor antagonistangiotensin receptor antagonistatrial fibrillationbeta blockerscardiac amyloidosiscardiac failurecardiogenic shockcardiomyopathycardiomyopathy in pregnancycardio-oncologychronic heart failurecongestive heart failurediabetesguideline-directed medical therapyheart failureheart failure rehabilitationheart failure with mildly reduced ejection fractionheart failure with preserved ejection fractionheart failure with reduced ejection fractionmineralocorticoid receptor antagonistsmitral regurgitationpalliative carereduced ejection fractionright heart pressuresacubitril-valsartanSGLT2 inhibitorssocial determinants of healthsodium glucose co-transporter 2systolic heart failurevalvular heart disease

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 6 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.